Bloodline

Young people with bleeding disorders score in the David Beckham Football Academy, Greenwich
InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment Of Paroxysmal Nocturnal Hemoglobinuria (PNH)
FDA Clears Osmetech's Warfarin Sensitivity Test And New ESensor® XT-8 Platform

1. The Crookston Collection (Slide Images)    (Category: References)
2. HEMEX Laboratories    (Category: Treatment and Research Centers)
3. BMTSAA    (Category: Organizations)
4. Non-Hodgkin's Lymphoma Cyberfamily    (Category: Patient Information)
5. WFCC-MIRCEN World Data Centre for Microorganisms (WDCM)    (Category: References)

Tyrosine Kinase Inhibitors and Stem Cell Transplantation – Shaping The Treatment Landscape Of CML

Article Index
Tyrosine Kinase Inhibitors and Stem Cell Transplantation – Shaping The Treatment Landscape Of CML
CME Information
Presentations

Page 3 of 3

	Tyrosine Kinase Inhibitors: Redefining Treatment Algorithms for CML Jerald P. Radich, MD Professor of Medicine University of Washington School of Medicine Member, Clinical Research Division Fred Hutchinson Cancer Research Center Seattle, Washington View Presentation
	Stem Cell Transplantation in Patients With CML: When Should It Be Used? Sergio A. Giralt, MD Associate Professor of Medicine Clinical Medical Director Department of Blood and Marrow Transplantation University of Texas M.D. Anderson Cancer Center Houston, Texas View Presentation
	New Options for Patients With Imatinib Resistance Neil P. Shah, MD, PhD Assistant Professor of Hematology/Oncology Department of Medicine University of California, San Francisco School of Medicine San Francisco, California View Presentation
	Question and Answer Session Chairman and Faculty Panel View Presentation
	Download a PDF of the Program Post-Test and Activity Evaluation/Request for CME Credit Form